Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound

Alzheimer’s disease (AD) is an intractable neurodegenerative disease that leads to dementia, primarily in elderly people. The neurotoxicity of amyloid-beta (Aβ) and tau protein has been demonstrated over the last two decades. In line with these findings, several etiological hypotheses of AD have been proposed, including the amyloid cascade hypothesis, the oxidative stress hypothesis, the inflammatory hypothesis, the cholinergic hypothesis, et al. In the meantime, great efforts had been made in developing effective drugs for AD. However, the clinical efficacy of the drugs that were approved by the US Food and Drug Association (FDA) to date were determined only mild/moderate. We recently adopted a vanadium compound bis(ethylmaltolato)-oxidovanadium (IV) (BEOV), which was originally used for curing diabetes mellitus (DM), to treat AD in a mouse model. It was shown that BEOV effectively reduced the Aβ level, ameliorated the inflammation in brains of the AD mice, and improved the spatial learning and memory activities of the AD mice. These finding encouraged us to further examine the mechanisms underlying the therapeutic effects of BEOV in AD. In this review, we summarized the achievement of vanadium compounds in medical studies and investigated the prospect of BEOV in AD and DM treatment.

Theoretical Description for Omeprazole Cathodical Electrochemical Determination, Assisted by Omeprazole Electrochemical Determination, Assisted by the Composite Poly(1,2,4-triazole) – VO(OH)

In this work, we describe theoretically the possibility of omeprazole electrochemical determination, assisted by the composite containing vanadium oxyhydroxide as an active substance and the polymer of 1,2,4-triazolic derivative as a mediator. The omeprazole molecule undergoes a sulfoxide to sulfide reduction process over a trivalent vanadium compound. The vanadium oxyhydroxide, at its turn, may be oxidized to a tetravalent state, represented in two forms. The electroanalytical process behavior will be illustrated by a trivariate equation-set, analysis of which confirms the efficiency of the composite of poly (1,2,4-triazole) with VO(OH). Vanadium (III) oxyhydroxide may be efficiently used for omeprazole detection both in pharmaceutical formulations, food, and biological liquids.

Novel structurally-stable Na-rich Na4V2O7 cathode material with high reversible capacity by utilization of anion redox activity

A sodium-rich vanadium compound, Na4V2O7, is investigated as a cathode material for sodium-ion batteries, with a high reversible capacity of 194 mA h g−1 after activating to 4.7 V.

2D heterogeneous vanadium compound interfacial modulation enhanced synergistic catalytic hydrogen evolution for full pH range seawater splitting

A composite material (VS2@V2C) of vertically mosaic VS2 nanosheets was grown on a V2C substrate for electrolyzing water in the full pH range for hydrogen evolution.

Lipid nanoparticles – Metvan: revealing a novel way to deliver a vanadium compound to bone cancer cells

A new Metvan-NLC compound was developed to improve Metvan's biopharmaceutical profile and antitumor efficacy.

The vanadium compounds: chemistry, synthesys, insulinomimetic properties

The review considers the biological role of vanadium, its participation in various processes in humans and other mammals, and the anti-diabetic effect of its compounds. Vanadium salts have persistent hypoglycemic and antihyperlipidemic effects and reduce the probability of secondary complications in animals with experimental diabetes. The review contains a detailed description of all major synthesized vanadium complexes having antidiabetic activity. Currently, vanadium complexes with organic ligands are more effective and safer than the inorganic salts. Despite the proven efficacy of these compounds as the anti-diabetic agents in animal models, only one organic complex of vanadium is currently under the second phase of clinical trials. All of the considered data suggest that vanadium compound are a new promising class of drugs in modern pharmacotherapy of diabetes.

Structural and redox requirements for the action of anti-diabetic vanadium compounds

The transformation of non-oxido VIVto oxido VIVspecies under physiological conditions is necessary for a vanadium compound to exhibit pharmacological anti-diabetic activity.